Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 19/20 | 0.76 |
| ▸ | CTSL | P07711 | 9/20 | 0.56 |
| ▸ | CTSS | P25774 | 7/20 | 0.56 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6581041 | 0.93 | CTSK (0.88) | CTSKCTSLCTSSCTSBMAPK1 | |
| SCHEMBL6580320 | 0.93 | CTSK (0.82) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6580495 | 0.92 | CTSK (0.77) | CTSKCTSLCTSSCTSBMAPK1 | |
| SCHEMBL4686405 | 0.91 | CTSK (0.70) | CTSKCTSLCTSSCTSBMAPK1 | |
| SCHEMBL4686404 | 0.91 | CTSK (0.70) | CTSKCTSLCTSSCTSBMAPK1 | |
| SCHEMBL6580683 | 0.88 | CTSK (0.89) | CTSKCTSLCTSSCTSBMAPK1 | |
| SCHEMBL6580629 | 0.86 | CTSK (1.00) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6580628 | 0.86 | CTSK (1.00) | CTSKCTSLCTSSCTSB | |
| SCHEMBL6580797 | 0.86 | CTSK (0.76) | CTSKCTSLCTSSCTSB | |
| SCHEMBL4328786 | 0.86 | CTSK (0.62) | CTSKCTSLCTSSCTSBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0936912-B1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
| EP-0936912-A4 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0936912-A1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998005336-A1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128476-A1 | Inhibitors of cysteine protease | CTRC, RCE1, CTRL | CTSK 100/4885CTSL 8/4885CTSS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.